{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:31:09Z","timestamp":1784633469355,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the majority of patients with Hodgkin lymphoma are cured with initial therapy, 10% to 15% of patients with early stage disease and 15% to 30% of patients with advanced disease have primary refractory or relapsed lymphoma. For younger patients whose disease is sensitive to second\u2010line therapy, more than half of patients will experience long\u2010term disease control with high\u2010dose chemotherapy\/autologous stem cell rescue (ASCT). For those patients who are chemotherapy refractory, relapse after, or are ineligible for ASCT, brentuximab vedotin, and checkpoint, inhibitors are highly active, although the majority of patients will ultimately experience recurrent lymphoma. Allogeneic transplant is curative in a subset of patients but may be associated with significant toxicity. Novel targeted and immunotherapy approaches, including chimeric antigen receptor T\u2010cell therapy, are currently being studied in clinical trials with promising early results.<\/jats:p>","DOI":"10.1002\/hon.2589","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T08:00:51Z","timestamp":1560326451000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease"],"prefix":"10.1002","volume":"37","author":[{"given":"Ann S.","family":"LaCasce","sequence":"first","affiliation":[{"name":"Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10661"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz009"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_12_14_1","first-page":"1635","article-title":"Phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: part 3 (concurrent dosing) results and updated progression\u2010free survival results from parts 1 and 2 (staggered dosing)","author":"Advani RH","year":"2018","journal-title":"ASH"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1300898"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-362475"},{"issue":"21","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood.V120.21.2740.2740","article-title":"Everolimus forRelapsed\/Refractory Classical Hodgkin Lymphoma: Multicenter, Open\u2010Label,Single\u2010Arm, Phase 2 Study","volume":"120","author":"Johnston P","year":"2012","journal-title":"Blood"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"e_1_2_12_20_1","first-page":"928","article-title":"Phase 1 study of Adct\u2010301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine\u2010based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma","author":"Hamadani M","year":"2018","journal-title":"ASH"},{"key":"e_1_2_12_21_1","first-page":"680","article-title":"CD30\u2010chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL)","author":"Ramos C","year":"2018","journal-title":"ASH"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3179"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2589","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:32:44Z","timestamp":1694334764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":21,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1002\/hon.2589"],"URL":"https:\/\/doi.org\/10.1002\/hon.2589","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"2019-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}